| Literature DB >> 31695793 |
Cheng Li1,2, Xiao-Quan Yang1, Jie An1, Kai Cheng1, Xiao-Lin Hou1, Xiao-Shuai Zhang1, Xian-Lin Song1, Kai-Chen Huang3, Wei Chen1, Bo Liu1, Yuan-Di Zhao1,4, Tian-Cai Liu3,5.
Abstract
Despite burgeoning development of nanoplatform made in the past few years, it remains a challenge to produce drug nanocarrier that enables requested on/off drug release. Thus, this study aimed to develop an ideal near-infrared light-triggered smart nanocarrier for targeted imaging-guided treatment of cancer that tactfully integrated photothermal therapy with chemotherapy to accurately control drug release time and dosage.Entities:
Keywords: cancer therapy; charge reversible; dendritic mesoporous silica; drug delivery; protein engineering
Year: 2019 PMID: 31695793 PMCID: PMC6831479 DOI: 10.7150/thno.37047
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
Figure 1Schematic illustration of the synthesis route of Ag2S@M/D-P-RGD, tumor targeted fluorescence-photoacoustic imaging and combined chemo-photothermal therapy.
Figure 2TEM and high-resolution TEM (inset) images of Ag2S QD (A), Ag2S@M (B) and EDX spectrum (inset), and Ag2S@M-P-RGD (C); high-angle annular dark field image (HAADF) of Ag2S@M (D); nitrogen adsorption-desorption isothermal curve (E) and pore size distribution (inset); fluorescence spectra of Ag2S QD and Ag2S@M (F); hydrated particle size distribution (G), zeta potentials (inset) and UV-Vis spectra (H) of different nanoparticles in pure water; fluorescence (I) and photoacoustic (J) images of Ag2S@M at different concentrations.
Figure 3Zeta potential changes of cys-P-RGD, Ag2S@M and Ag2S@M-P-RGD under different pH conditions (A); relative protein adsorptions of Ag2S@M and Ag2S@M-P-RGD (0.4 mg/mL) incubated with BSA for 12 h and 24 h under different pH conditions (B); pharmacokinetics of Ag2S@M and Ag2S@M-P-RGD (100 mg/kg) (C); mRNA expression levels of the inflammatory cytokines, IL-6, IL-1β and TNF-α, were assessed in RAW 264.7 macrophages incubated with Ag2S@M and Ag2S@M-P-RGD (100 µg/mL) for 24 h (D); hemolysis of Ag2S@M and Ag2S@M-P-RGD (E); DOX release curves of Ag2S@M/D-P-RGD (2.5 mg/mL) with and without laser irradiation at pH 7.4 and 5.4 (F). *: p<0.05, **: p<0.01.
Figure 4White light, NIR fluorescence and photoacoustic images of HeLa and MCF-7 cells incubated with Ag2S@M/D-P and Ag2S@M/D-P-RGD (A); CLSM images of HeLa cells incubated with Ag2S@M/D-P, Ag2S@M/D-P-RGD and Ag2S@M/D-P-RGD with c(RGDyK) pre-blocking (denoted as “RGD blocking”) (B); biological TEM images of Ag2S@M-P-RGD incubated with HeLa cells (C); survival rate of HeLa and MCF-7 cells incubated with Ag2S@M-P and Ag2S@M-P-RGD at different concentrations (D).
Figure 5Evaluation of the therapy effect in vitro. MTT assay of survival rate of HeLa cells treated with different probes (A); calcein and PI stained fluorescence imaging images of HeLa cells were treated with Ag2S@M-P-RGD (100 µg/mL) irradiated with different intensity laser and time (B); flow cytometry of the apoptosis induced by different treatments (at the same concentration of DOX (5 µg/mL)) (C); CLSM images of HeLa and MCF-7 cells incubated with Ag2S@M/D-P-RGD irradiated with and without laser (D). **: p<0.01.
Figure 6FLI at different time points after tail vein injection of Ag2S@M-P-RGD (100 mg/kg) into HeLa (A) and MCF-7 (C) tumor-bearing nude mice; FLI at different time points after tail vein injection of Ag2S@M-P (100 mg/kg) into HeLa tumor-bearing nude mice (B); PAI at different time points after tail vein injection of Ag2S@M-P-RGD (100 mg/kg) into HeLa tumor-bearing nude mice (D); distribution of Ag2S@M-P-RGD in major organs of HeLa tumor-bearing nude at different time points after tail vein injection (E); infrared thermal imaging (F) and temperature variation curves (G) of tumor site irradiated by laser after 12 h of intravenous injection 200 µL PBS, Ag2S@M-P-RGD (10 mg/mL) and Ag2S@M/D-P-RGD (10 mg/mL).
Figure 7Schematic illustration of treatment route of single and multiple short-term laser irradiation (A); tumor growth after different treatments (B); body weights (D) and images (F) of mice with various treatments during 24 d; tumor mass in different groups at end of treatment (C); masson staining of tumor focal and peripheral skin of mice irradiated with single and multiple short-term laser irradiation (E). *: p<0.05, **: p<0.01.